Extracellular vesicle encapsulated nicotinamide delivered via a trans-scleral route provides retinal ganglion cell neuroprotection

• Published in: Acta neuropathologica communications 2024-04, Vol.12 (1), p.65-65, Article 65
• Main Authors: Kim, Myungjin, Kim, Jun Yong, Rhim, Won-Kyu, Cimaglia, Gloria, Want, Andrew, Morgan, James E, Williams, Pete A, Park, Chun Gwon, Han, Dong Keun, Rho, Seungsoo
• Format: Article
• Language: English
• Subjects: Analysis; Animals; Blindness; Drug delivery systems; Drug Delivery Systems - methods; Drugs; Extracellular vesicle; Extracellular Vesicles - drug effects; Extracellular Vesicles - metabolism; Ganglion; Glaucoma; Glaucoma - drug therapy; Glaucoma - metabolism; Male; Medicin och hälsovetenskap; Mice; Mice, Inbred C57BL; Neuroprotection; Neuroprotection - drug effects; Neuroprotective Agents - administration & dosage; Neuroprotective Agents - pharmacology; Niacinamide; Niacinamide - administration & dosage; Niacinamide - pharmacology; Nicotinamide; Patient compliance; Retinal ganglion cell; Retinal Ganglion Cells - drug effects; Retinal Ganglion Cells - metabolism; Sclera - drug effects; Sclera - metabolism; Trans-scleral route; Vehicles
• ISSN: 2051-5960; 2051-5960
• DOI: 10.1186/s40478-024-01777-0

The progressive and irreversible degeneration of retinal ganglion cells (RGCs) and their axons is the major characteristic of glaucoma, a leading cause of irreversible blindness worldwide. Nicotinamide adenine dinucleotide (NAD) is a cofactor and metabolite of redox reaction critical for neuronal survival. Supplementation with nicotinamide (NAM), a precursor of NAD, can confer neuroprotective effects against glaucomatous damage caused by an age-related decline of NAD or mitochondrial dysfunction, reflecting the high metabolic activity of RGCs. However, oral supplementation of drug is relatively less efficient in terms of transmissibility to RGCs compared to direct delivery methods such as intraocular injection or delivery using subconjunctival depots. Neither method is ideal, given the risks of infection and subconjunctival scarring without novel techniques. By contrast, extracellular vesicles (EVs) have advantages as a drug delivery system with low immunogeneity and tissue interactions. We have evaluated the EV delivery of NAM as an RGC protective agent using a quantitative assessment of dendritic integrity using DiOlistics, which is confirmed to be a more sensitive measure of neuronal health in our mouse glaucoma model than the evaluation of somatic loss via the immunostaining method. NAM or NAM-loaded EVs showed a significant neuroprotective effect in the mouse retinal explant model. Furthermore, NAM-loaded EVs can penetrate the sclera once deployed in the subconjunctival space. These results confirm the feasibility of using subconjunctival injection of EVs to deliver NAM to intraocular targets.